Asymmetric Primaquine and Halogenaniline Fumardiamides as Novel Biologically Active Michael Acceptors
AbstractNovel primaquine (PQ) and halogenaniline asymmetric fumardiamides 4a–f, potential Michael acceptors, and their reduced analogues succindiamides 5a–f were prepared by simple three-step reactions: coupling reaction between PQ and mono-ethyl fumarate (1a) or mono-methyl succinate (1b), hydrolysis of PQ-dicarboxylic acid mono-ester conjugates 2a,b to corresponding acids 3a,b, and a coupling reaction with halogenanilines. 1-[bis(Dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU) was used as a coupling reagent along with Hünig′s base. Compounds 4 and 5 were evaluated against a panel of bacteria, several Mycobacterium strains, fungi, a set of viruses, and nine different human tumor cell lines. p-Chlorofumardiamide 4d showed significant activity against Staphylococcus aureus,Streptococcus pneumoniae and Acinetobacter baumannii, but also against Candida albicans (minimum inhibitory concentration (MIC) 6.1–12.5 µg/mL). Together with p-fluoro and p-CF3 fumardiamides 4b,f, compound 4d showed activity against Mycobacterium marinum and 4b,f against M. tuberculosis. In biofilm eradication assay, most of the bacteria, particularly S. aureus, showed susceptibility to fumardiamides. m-CF3 and m-chloroaniline fumardiamides 4e and 4c showed significant antiviral activity against reovirus-1, sindbis virus and Punta Toro virus (EC50 = 3.1–5.5 µM), while 4e was active against coxsackie virus B4 (EC50 = 3.1 µM). m-Fluoro derivative 4a exerted significant cytostatic activity (IC50 = 5.7–31.2 μM). Acute lymphoblastic leukemia cells were highly susceptible towards m-substituted derivatives 4a,c,e (IC50 = 6.7–8.9 μM). Biological evaluations revealed that fumardiamides 4 were more active than succindiamides 5 indicating importance of Michael conjugated system. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 3504 KB)
Share & Cite This Article
Rajić, Z.; Beus, M.; Michnová, H.; Vlainić, J.; Persoons, L.; Kosalec, I.; Jampílek, J.; Schols, D.; Keser, T.; Zorc, B. Asymmetric Primaquine and Halogenaniline Fumardiamides as Novel Biologically Active Michael Acceptors. Molecules 2018, 23, 1724.
Rajić Z, Beus M, Michnová H, Vlainić J, Persoons L, Kosalec I, Jampílek J, Schols D, Keser T, Zorc B. Asymmetric Primaquine and Halogenaniline Fumardiamides as Novel Biologically Active Michael Acceptors. Molecules. 2018; 23(7):1724.Chicago/Turabian Style
Rajić, Zrinka; Beus, Maja; Michnová, Hana; Vlainić, Josipa; Persoons, Leentje; Kosalec, Ivan; Jampílek, Josef; Schols, Dominique; Keser, Toma; Zorc, Branka. 2018. "Asymmetric Primaquine and Halogenaniline Fumardiamides as Novel Biologically Active Michael Acceptors." Molecules 23, no. 7: 1724.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.